

# Special Issue

## Diagnosis of Prostate Cancer

### Message from the Guest Editors

Prostate cancer remains one of the leading malignancies for new diagnoses and cancer-related mortality. Over the past decade, the diagnosis of prostate cancer has undergone marked changes with new imaging and biopsy techniques (targeted and transperineal) and the use of deep learning and genomic testing to better stratify risk prognostication and potentially individualize treatment decisions for men diagnosed with prostate cancer. These new diagnostic tests and imaging methods have already been shown to reduce the burden of prostate cancer by increasing active surveillance of low-risk prostate cancers and indicating the need for primary therapy in men who harbor clinically localized, aggressive prostate cancer. Understanding how to integrate these strategies is crucial to facilitating a greater quality of care for prostate cancer patients. In this summary, we have invited leaders in prostate cancer research to review each of the new diagnostic and management tests for prostate cancer.

---

### Guest Editors

Dr. Simon P. Kim

University of Colorado Health Sciences Center, Denver, United States

Dr. Rodrigo R. Pessoa

University of Colorado Health Sciences Center, Denver, United States

---

### Deadline for manuscript submissions

closed (31 March 2021)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/51531](https://mdpi.com/si/51531)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)